HUYABIO International Announces HBI-8000 and Nivolumab Combination Reduces the Risk of Disease Progression by 27% in Patients with Advanced Melanoma in Phase 3 Trial

Oral HBI-8000 plus intravenous nivolumab demonstrated a statistically significant and clinically meaningful improvement in progression-free survival compared with nivolumab alone, reducing the risk of disease progression or death by 27% Median progression-free survival was 11.7 months...

Summary aggregated from PR Newswire's public RSS feed. The full reporting belongs to PR Newswire — please read it on their site.